call 1800 257 600 email [email protected]

Magnetic Resonance Imaging (MRI) Guided Stereotactic Adaptive Radiotherapy for Targeting Abdominal Cancer

NCT 06604533

Brief Summary

The aim of this study is to investigate the effect of MRI-guided adaptive stereotactic radiotherapy on local control, survival, and toxicity in the treatment of oligometastatic cancer to the abdomen.

Intervention / Treatment 

  • Procedure: Intervention: MRI-Linac SABR

Inclusion Criteria:

  • Aged 18 years or older
  • Patients with diagnosis of oligometastatic disease from primary colorectal, upper gastrointestinal (e.g. gastric, oesophagus, pancreatic), breast, non-small cell lung, renal cell, or gynaecological malignancy. Oligometastatic disease with controlled primary disease* and maximum total of 5 metastatic lesions in a maximum of 2 different organ systems in any of the following sites:
    1. Liver
    2. Adrenal
    3. Abdomino-pelvic lymph node
    4. Other abdominal site e.g. pancreatic, renal.
    5. Other pelvic site
    6. Bony or lung is allowed only if in conjunction with an abdominal site above
  • De novo or metachronous oligometastatic disease where the original tumour site has been treated with curative intent.
    • Controlled primary disease in metachronous oligometastastic disease defined as at least 3 months since original tumour treated with curative intent and no progression at primary site
    • Controlled primary disease in de novo oligometastatic disease defined as primary tumour site treated with curative intent and no progression at primary site
  • Oligometastatic disease: Histological confirmation of primary malignancy (histological confirmation of metastasis is not mandatory but should be performed in any situation where there is any diagnostic uncertainty).
  • All oligometastatic sites treatable with SABR.

OR

  • Patients with oligo-progressive / oligo-persistent disease in maximum total of 2 oligo-progressive abdominal metastases and in a maximum 2 different organ systems
  • Visible imaging defined targets and suitable for treatment with SABR
  • Childs Pugh A to B7 (in case of liver treatment)
  • ECOG 0 -2
  • Patient consented

Keep up with Rare Cancers Australia

Inside Rare is a monthly newsletter that shares the latest news, events and stories connecting the rare community.